Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

LESSONS LEARNED: A biweekly TAS‐102 plus BEV schedule in patients with heavily pretreated mCRC showed equivalent efficacy with less toxicity compared with the current schedule of TAS‐102 plus BEV combination. Biweekly TAS‐102 plus BEV combination could reduce unnecessary dose reduction of TAS‐102, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Satake, Hironaga, Kato, Takeshi, Oba, Koji, Kotaka, Masahito, Kagawa, Yoshinori, Yasui, Hisateru, Nakamura, Masato, Watanabe, Takanori, Matsumoto, Toshihiko, Kii, Takayuki, Terazawa, Tetsuji, Makiyama, Akitaka, Takano, Nao, Yokota, Mitsuru, Okita, Yoshihiro, Matoba, Koreatsu, Hasegawa, Hiroko, Tsuji, Akihito, Komatsu, Yoshito, Yoshino, Takayuki, Yamazaki, Kentaro, Mishima, Hideyuki, Oki, Eiji, Nagata, Naoki, Sakamoto, Junichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108052/
https://www.ncbi.nlm.nih.gov/pubmed/32666647
http://dx.doi.org/10.1634/theoncologist.2020-0643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108052/
https://www.ncbi.nlm.nih.gov/pubmed/32666647
http://dx.doi.org/10.1634/theoncologist.2020-0643

Ejemplares similares